Correction: ICONOVO AB PUBLISHES THE ANNUAL REPORT 2024 IN ENGLISH

Wrong annual report initially attached to this press release; hereby corrected. The abbreviated annual report 2024 in English is attached to this press…

ICONOVO AB PUBLISHES THE ANNUAL REPORT 2024 IN ENGLISH

The abbreviated annual report 2024 in English is attached to this press release and is now available on the company's website, www.iconovo.se. ContactsJohan Wäborg,…

Iconovo’s nomination committee proposes election of two new board members

Iconovo AB today announces that the company’s Nomination Committee proposes that Erik Westerlund and Andreas Engström are elected as new members of the Board of Directors at the annual general meeting on 9 June 2025. The Nomination Committee further proposes re-election of Berndt Axelsson, Mats Johansson, Orest Lastow and Carl Lindgren as members of the Board of Directors. The current board members Agneta Walhagen and Erik Ekman have declined re-election.

QUARTERLY REPORT Q1 2025

SIGNIFICANT EVENTS DURING 1 JANUARY – 31 MARCH 2025Iconovo and Lonza have entered a collaboration to develop spray-dried formulations of an intranasal…

Iconovo resolves on a rights issue of shares of approximately SEK 36.6 million subject to approval by extraordinary general meeting

The Board of Directors of Iconovo AB (“Iconovo” or the “Company”) has today resolved to carry out a share issue of approximately SEK 36.6 million before deduction of issue costs with preferential rights for existing shareholders (the “Rights Issue”). The subscription price is SEK 1.15 per share. The primary purpose of the Rights Issue is to support out-licensing activities for ICOpre with the aim of achieving separate or combined license agreements, to provide advisory services to Amneal in the development of a budesonide/formoterol product in ICOres, and to further develop the intranasal semaglutide project up to preclinical proof-of-concept. The Rights Issue is conditional upon approval by an extraordinary general meeting in the Company, scheduled to be held on May 12, 2025. The Rights Issue is covered to 100 percent through subscription intentions, subscription commitments, and guarantee commitments. The notice to the extraordinary general meeting will be published through a separate press release. Due to the Rights Issue, the Board of Directors has decided to postpone the annual general meeting to June 9, 2025.

Iconovo implements organizational changes to increase focus on the commercialization of the company’s fully developed inhalation platforms

Iconovo AB (publ), a leading company in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, today announces that the company is planning an organizational change that is expected to reduce the cost base by approximately SEK 14–16 million on an annual basis from the third quarter of 2025. The background is that the demand for internal resources in product development has decreased following the successful development of the company's five inhaler platforms. Iconovo will now focus on the commercialization of its existing products, including ICOpre®-based generic versions of Ellipta® pharmaceuticals, and on the development of semaglutide-based pharmaceuticals in ICOone® Nasal.

Iconovo receives new patent for ICOres® in Europe

Iconovo AB (publ), which develops complete inhalation products for a global market, today announced that the European Patent Office (EPO) intends to approve the company's application for a patent for the inhaler platform ICOres®. ICOres® is already used in several of Iconovo's customer projects, and the new patent strengthens the intellectual property rights, benefiting customers who will launch pharmaceutical products based on the company's unique inhaler in the future.

Iconovo receives a grant of SEK 670,000 from Innowwide to target the Japanese market

Iconovo AB (publ), a leading player in the development of inhalable drugs, based on proprietary inhalers and dry powder formulations, today announces that the company has received a grant of SEK 670,000 from Innowwide. The grant will be used to conduct a market study with the aim of introducing the company's products and services to the Japanese market. The project will be carried out during the period May to November.

Year-end report 1 January – 31 December 2024

27 February 2025

Iconovo and Lonza to collaborate on the formulation development of an intranasal biologic

Iconovo AB (publ), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, today announced that Iconovo and Lonza has initiated a collaboration to develop spray-dried formulations of an intranasal biologic for Iconovo’s proprietary intranasal device ICOone Nasal®. This project, with a reformulated substance for obesity, is the first in Iconovo’s strategic initiative to reformulate known pharmaceuticals and replace injections and oral treatments with inhalation.